Johnson & Johnson (J&J) has been a Vestact recommended stock since 2012. Over those 13 years it has returned around 150%, underperforming the S&P500 which was up 316% in the same period. Thanks to multiple lawsuits, a lack of innovative products and a complacent corporate culture, the J&J share price has even underperformed inflation over the last 5 years. We can do better.

We suggest you sell your J&J and use the proceeds to buy Eli Lilly. Eli Lilly seems to be doing everything right - they have new and innovative products, are growing fast and investing strongly in the future.

Please respond to this email and let us know if you are happy to make the switch. If you already have a large Eli Lilly position we may suggest you add to something else.